Questionnaire survey of patients who have started home self-injection of CGRP-related monoclonal antibodies

Abstract

  A questionnaire survey was conducted to clarify the thoughts and problems of patients receiving home self-injection of CGRP-related monoclonal antibodies, and to devise and implement better guidance so that patients can safely and securely perform home self-injection.
  The subjects were 115 migraine patients who had started home self-injection of CGRP-related monoclonal antibodies. Although 57％ of the patients said they had concerns before starting self-injection, 90％ of patients said they were happy with self-injection, and the most common answer regarding the benefits was that it reduced the number of hospital visits. The fact that more patients than expected answered that they had no worries about self-injection was attributed to patients’ expectations about the effects of CGRP-related monoclonal antibodies and the simplicity of the autoinjector. Further, the successful experience of being able to self-inject without failure during practice was thought to have boosted their confidence. The increase in the number of patients self-injecting at home is not only beneficial for patients, but also for nurses, as it reduces their workload for in-hospital injections, which is considered to be beneficial for both parties.